The purpose of this study is to evaluate the durability of effect of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment and to characterize the effects of milnacipran on multiple symptoms of fibromyalgia, as demonstrated by changes in symptoms following the discontinuation of milnacipran.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
340
Placebo tablets administered orally twice daily
Milnacipran tablets administered orally twice daily
Time to Loss of Therapeutic Response (LTR)
Time to loss of therapeutic response is defined as the time from the first dose of double-blind investigational product to the first visit when a patient has a \< 30% reduction in Visual Analog Scale (VAS) pain score from pre-milnacipran exposure OR a worsening of fibromyalgia requiring, in the judgment of the investigator, an alternative treatment
Time frame: From baseline Visit 3 (week 5) to Visit 7 (week 17)
Time to Worsening in Patient Global Impression of Change (PGIC)
Time to worsening in Patient Global Impression of Change is defined as the time from the first dose of double-blind investigational product to the first visit when a patient has a PGIC score of 6 or 7. The PGIC is an efficacy assessment on a scale of 1-7 taken at visits 4, 5, 6 and 7. The wording of the assessment is as follows: "Since the start of the study, overall my fibromyalgia is:" 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No Change, 5=Minimally Worse, 6=Much Worse, and 7=Very Much Worse.
Time frame: From baseline Visit 3 (week 5) to Visit 7 (week 17)
Time to Worsening in Multidimensional Assessment of Fatigue (MAF)
Time to worsening in MAF is defined as the time from the first dose of double-blind investigational product to the first visit when a patient has a 10-point increase from baseline in the global index of fatigue in MAF. Scores range from 1 (no fatigue) to 50 (severe fatigue). The MAF contains 16 items measuring 4 dimensions of fatigue: severity, distress, degree of interference in activities of daily living, and timing. Fourteen of the items contain numerical rating scales (increasing in severity); the remaining 2 items have multiple-choice responses (decreasing in severity).
Time frame: From baseline Visit 3 (week 5) to Visit 7 (week 17)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Forest Investigative Site 062
Birmingham, Alabama, United States
Forest Investigative Site 065
Birmingham, Alabama, United States
Forest Investigative Site 012
Tucson, Arizona, United States
Forest Investigative Site 007
Fresno, California, United States
Forest Investigative Site 032
Pismo Beach, California, United States
Forest Investigative Site 025
Sacramento, California, United States
Forest Investigative Site 019
San Diego, California, United States
Forest Investigative Site 057
Santa Ana, California, United States
Forest Investigative Site 039
Vista, California, United States
Forest Investigative Site 050
Cromwell, Connecticut, United States
...and 48 more locations